FDC reported Q2 revenue down 7.9% to 473 Cr and PAT down 60.6% to 28 Cr, mainly due to lower domestic sales and strategic R&D/employee costs.

Export formulations grew 3.5% in Q2, with US supplies showing recovery.

The company received US FDA approvals for two ophthalmic solutions.

Electral rose to 15th rank in IPM.